HEK293T/Human A3 β-Arrestin Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-A-0021A | Inquiry |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The A3 adenosine receptor (ADORA3) is a Gi-coupled receptor primarily expressed on immune cells (e.g., mast cells), in the CNS (glia), and the eye. It has context-dependent roles, offering anti-inflammatory, cardioprotective, and neuroprotective benefits, but can promote inflammation and apoptosis if overactivated. This makes it a promising yet complex target for treating inflammatory/autoimmune diseases, ischemic injury, and certain cancers.
ScreeningBio’s HEK293T/Human A3 β-Arrestin cell line is an ideal tool for studying GPCR/β-arrestin interactions. In this system, the GPCR C-terminus is fused to a smallBiT tag, and the β2-arrestin N-terminus is fused to a largeBiT tag. Upon receptor activation, GPCR/β-arrestin interaction brings the two fragments together to reconstitute an active NanoLuc enzyme, which can be quantified using the NanoBiT substrate. This cell line is designed to evaluate a compound’s ability to activate the β-arrestin signaling pathway.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | ADORA3 |
Accession Number | NM_000677 (Hs) |
Parental Line | HEK293T |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The adenosine A3 receptor (ADORA3) is a subtype of the adenosine receptor family, belonging to the Gi protein-coupled receptor class. Its expression in the body is relatively restricted, primarily found on peripheral immune cells, within the central nervous system, and in the eye.
Its function is bidirectional: short-term or low-intensity activation mediates anti-inflammatory effects, cardioprotective ischemic preconditioning, and neuroprotection; whereas high-intensity or sustained activation may lead to pro-inflammatory responses and apoptosis.
Consequently, ADORA3 is a complex regulatory target. Selective agonists hold potential for treating inflammatory and autoimmune diseases and ischemia/reperfusion injury, while its antagonists may be explored for certain cancer therapies.